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Background: Low-molecular-weight heparin (LMWH) is recommended and commonly used for extended
treatment of cancer-associated thrombosis (CAT), but its superiority over warfarin has been demonstrated in only
one randomised study. We report here the rationale, design and a priori analysis plans of Comparison of Acute
Treatments in Cancer Haemostasis (CATCH; NCT01130025), a multinational, Phase III, open-label, randomised
controlled trial comparing tinzaparin with warfarin for extended treatment of CAT.
Methods/Design: The primary objective is to assess the efficacy of tinzaparin in preventing recurrent venous
thromboembolism (VTE) in patients with active cancer and acute, symptomatic proximal deep vein thrombosis
and/or pulmonary embolism. The secondary objectives are to determine: safety of tinzaparin given over 6 months;
clinical and laboratory markers for recurrent VTE and/or major bleeding; 6-month overall mortality; incidence and
severity of post-thrombotic syndrome; patient-reported quality of life; and healthcare resource utilisation. Nine
hundred patients are randomised to receive tinzaparin 175 IU/kg once daily for 6 months or initial tinzaparin
175 IU/kg once daily for 5–10 days and dose-adjusted warfarin (target INR 2.0–3.0) for 6 months. The primary
composite outcome is time to recurrent VTE, including incidental VTE and fatal pulmonary embolism. All patients
are followed up to 6 months or death, whichever comes sooner. Blinded adjudication will be performed for all
reported VTE, bleeding events and causes of death. Efficacy will be analysed using centrally adjudicated results of all
patients according to intention-to-treat analysis. An independent Data Safety Monitoring Board is reviewing data at
regular intervals and an interim analysis is planned after 450 patients have completed the study.
Discussion: The results will add significantly to the knowledge of the efficacy, safety and cost effectiveness of
tinzaparin in the prevention of recurrent VTE in patients with cancer and thrombosis. Prospective data will emerge
on the clinical significance of incidental VTE and risk stratification in patients with CAT. Results on post-thrombotic
syndrome, quality of life and healthcare resource utilisation will inform decision makers on how to secure better
patient care. If tinzaparin is shown to be more effective than warfarin, CATCH will provide valuable confirmatory
data to support the use of the LMWH tinzaparin for extended treatment of CAT.
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Cancer and venous thromboembolism
Cancer patients are known to be at higher risk of develop-
ing venous thromboembolism (VTE) compared with the
general population [1-3]. VTE is a major cause of morbid-
ity and mortality and is the second most common cause
of death in patients with cancer [4,5]. Moreover, with the
increasing incidence and prevalence of cancer, combined
with more aggressive, often thrombogenic treatment regi-
mens and surgery, the prevalence of cancer-associated
thrombosis can be expected to increase.
The incidence of symptomatic VTE in cancer patients
varies widely, with reported rates of 2% to 30%. This vari-
ation is likely to reflect not only the natural history of
different tumour types [6-8] but also the influence of
tumour-related factors (e.g. tumour location, presence
of distant metastases) [1,7,9,10], treatment-related factors
(e.g. surgery, chemotherapy) [11,12] and patient-related
factors (e.g. older age, co-morbidities, multiple surgeries)
[9]. The true rate of VTE is probably even higher than
reported rates as many cases remain undetected. As part of
an increasing focus on staging procedures, treatment mo-
dalities, treatment outcomes and improving cancer sur-
vival, the significance of asymptomatic or incidental events
is becoming increasingly recognised [13]. Indeed, during
the past decade, computed tomography (CT) scans have
been used with greater frequency for the routine assess-
ment of cancer staging and disease monitoring and, con-
cordant with this, there has been increased reporting of
incidental VTE, especially pulmonary embolism (PE), in
cancer patients [14]. Neither the prognostic impact nor the
treatment of incidental PEs in cancer patients is completely
understood, but the consensus is that these events should
be treated [15]. This is supported by data showing that the
prevalence of incidental PE is clinically relevant and poten-
tially associated with an unfavourable outcome [16,17].
Treatment of VTE in cancer patients
Guidelines in Europe and North America recommend
long-term treatment of symptomatic VTE in all cancer
patients [18,19]. Major treatment objectives are to di-
minish the acute symptoms of deep vein thrombosis
(DVT) and/or PE, reduce recurrent thrombosis, and re-
duce both fatal and non-fatal PE. Treatment of VTE
should also reduce the incidence of long-term sequelae,
such as post-thrombotic syndrome (PTS). With im-
proved oncology treatment options leading to longer life
expectancy, the benefits of long-term treatment of VTE
are becoming increasingly relevant to patients with can-
cer. This trend towards better care might be expected to
have a positive impact on a patient’s quality of life
(QoL); however, relatively little is known about this im-
portant topic and further investigation of patient-
reported outcomes is warranted.For the general population, the standard treatment for
acute VTE consists of initial therapy with a low-
molecular-weight heparin (LMWH) followed by longer-
term treatment (3–6 months) with an oral vitamin K
antagonist (VKA). Although this approach can be effect-
ive for many patients, cancer patients have a substantial
risk of recurrent VTE. Several studies have reported in-
cidences of recurrent VTE as high as 20% in patients
with cancer [20,21]. However, studies on how to treat
and identify those at risk of recurrent VTE are limited
[22,23]. Moreover, the frequent monitoring and dose ad-
justments required for VKA treatment have a negative
impact on QoL [24]. Oral anticoagulant therapy with
VKAs or novel oral anticoagulants, e.g. dabigatran and
rivaroxaban, may also be problematic in patients with
cancer because of drug interactions, malnutrition, vomi-
ting and mucositis, and renal and liver dysfunction, all
of which can lead to unpredictable bioavailability and
variable levels of anticoagulation. Patients with advanced
cancer may also have problems swallowing oral medica-
tions. Furthermore, the efficacy and safety of novel oral
anticoagulants have yet to be determined in cancer pa-
tients and there is no antidote to reverse the anticoagu-
lant effect of these drugs in cases of severe bleeding or
when acute surgical intervention is necessary.
Unlike VKAs, LMWHs have predictable pharmacoki-
netic profiles and very few drug interactions [25]. LMWHs
have been shown to have clinical benefit over VKAs in the
secondary prevention of VTE in cancer patients [26-29].
Consequently, major consensus evidence-based guidelines
on anticoagulation recommend that LMWHs be used for
3–6 months for the treatment of acute VTE in patients
with active cancer (ASCO [30], ESMO [31], NCCN [32]
and ACCP [15]). Although only the CLOT study has dem-
onstrated statistically significant reduction in symptomatic
VTE using dalteparin compared with VKA [28] (Table 1),
all three major LMWHs (dalteparin, enoxaparin and
tinzaparin) are recommended in guidelines. In the CLOT
trial, dalteparin was given at a full, therapeutic dose for
the first month followed by 75–80% of the full dose from
month 2 to 6. In contrast, full doses of LMWH were
given throughout the entire treatment period in the
CANTHANOX, ONCENOX and LITE studies (Table 1).
Whether this latter approach would have resulted in lower
risks of VTE recurrence or higher risks of bleeding
in CLOT is unknown. None of these previous trials
addressed questions regarding PTS, QoL, predictors of
recurrence, and the cost effectiveness of LMWH mono-
therapy, all of which are important considerations for
long-term therapy in a complex patient population with
reduced life expectancy. Finally, the open-label design of
published trials and the perceived patient preference of
oral therapy over subcutaneous injections led the ACCP
to downgrade its previous 1A recommendation from the
Table 1 Randomised clinical trials of VTE treatment in patients with cancer (adapted from Khorana 2009 [18])
Study n Population Treatments Follow-up Outcomes Key limitations compared with the CATCH study design




Dalteparin qd (5–7 days)
+ warfarin* (6 months)
6 months Recurrent VTE (primary)
15.8% (W), 8.0% (D); P = 0.002
Full-dose dalteparin not maintained for entire 6-month
treatment period
Dalteparin qd (6 months)† Major bleeding
4% (W), 6.0% (D); P = 0.27
No outcomes for PTS, HRQoL, predictors of recurrence,
and healthcare resource utilisation
Main-LITE‡ [27] 200 Proximal DVT UFH + warfarin (6 days)




3 months: 10.0% (W), 6.0% (T)
12 months: 16.0% (W), 7.0% (T); P = 0.044
Duration of randomised treatment only 3 months
Tinzaparin qd (3 months)
Major bleeding
3 months: 7.0% (W), 7.0% (T)
Modest sample size with limited statistical power
CANTHANOX [29] 146 DVT and/or PE Enoxaparin qd (initial)
+ warfarin (3 months)
3 months Treatment failure§ (primary)
21.1% (W), 10.5% (E); P = 0.09




16.0% (W), 7.0% (E); P = 0.09
Duration of randomised treatment only 3 months
Small study with limited statistical power
Trial stopped early because of slow recruitment




(5 days) + warfarin
(6 months)
6 months Recurrent VTE (secondary)
10.0% (W), 6.9% (LD), 6.3% (HD)
Recurrent VTE was only a secondary objective (study did not
meet its primary objective, which was to recruit the necessary
number of patients within a 12-month time frame)
Small study with limited statistical power
Enoxaparin LD bid
(5 days) then LD qd
(6 months)
Enoxaparin LD bid
(5 days) then HD qd
(6 months)
Major bleeding
2.9% (W), 6.5% (LD), 11.1% (HD)
*Except in Spain and The Netherlands, where acenocoumarol was used; †full dose (200 IU/kg) for first month then reduced dose (~150 IU/kg) for the remaining 5 months; ‡cancer subpopulation; §composite endpoint
of recurrent VTE and/or major bleeding within 3-month treatment period.
Abbreviations: bid twice daily; D dalteparin, DVT deep vein thrombosis, E enoxaparin, HD high dose (1.5 mg/kg), HRQoL health-related quality of life, LD low dose (1.0 mg/kg), PE pulmonary embolism,
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addition, the lack of confirmatory studies may explain the
continued widespread use of VKAs [33,34]. To narrow
these gaps in knowledge, and to provide additional data to
support multiple guidelines that recommend prolonged
treatment with LMWH as the preferred anticoagulant for
cancer-associated thrombosis, we are conducting CATCH
(Comparison of Acute Treatments in Cancer Haemosta-
sis), a multinational, open-label, randomised controlled
trial designed to compare tinzaparin (innohep®, LEO
Pharma A/S) with warfarin for the extended treatment of
cancer-associated VTE.
Main study objectives
The main aim of CATCH is to compare the efficacy of
tinzaparin with warfarin in preventing the recurrence of
VTE in patients with active cancer. Secondary objectives
are: to assess the safety of long-term tinzaparin; to iden-
tify clinical risk factors for recurrent VTE and bleeding;
to assess overall mortality at 6 months; to identify the
possible role of coagulation parameters in predicting re-
current thrombosis or prognosis; to assess the incidence
and severity of PTS; to assess patient-reported QoL; and
to assess healthcare resource use for the treatment of
cancer-associated VTE.Tinzaparin 175 IU/kg once daily 
(N=450)
Screening period (-72 h
• Assess for study eligib
• Perform screening lab
• Obtain informed conse
Treatment period (D
• Scheduled visits on Days 1, 7, 14, 30, 60, 90, 120,
• From Day 30, patients will be contacted by telepho




Stratified for the following factors:
• Tumour (known distant metastasis, no distant me
• Geographical region (four separate regions)
• Known history of previously diagnosed VTE (yes 
Enrolment started August 2010
Figure 1 Study design, interventions and timelines.Methods
Study design
CATCH is a Phase III, multinational, concealed, randomi-
sed, active-controlled, open-label trial with blinded adjudi-
cation assessing the efficacy and safety of long-term
(6 months) tinzaparin therapy versus anticoagulation with
warfarin for the treatment of VTE in cancer patients
(Figure 1). It is being conducted in more than 160 sites
across five continents.
Study population
Adult patients (≥18 years or above legal age of consent)
with a diagnosis of active cancer and a histologically or
cytologically confirmed solid tumour (evidence of early-
stage, regionally advanced or metastatic disease) or
haematological malignancy are eligible for inclusion. Ac-
tive cancer is defined by any of the following: diagnosis
of cancer within the past 6 months; recurrent, regionally
advanced or metastatic disease; any treatment for cancer
during the previous 6 months; not in complete remission
of a haematological malignancy. Participants must also
have symptomatic and objectively confirmed acute prox-
imal DVT and/or PE (Table 2). Other inclusion criteria
include Eastern Cooperative Oncology Group (ECOG)




ay 1 to Day 180)
 150 and 180
ne 14 days after each monthly visit 
ent will be followed up by telephone in place of 
y 181 to Day 210)
 1:1 (Day 1)
tastasis, haematological malignancy)
or no)
Warfarin once daily (target INR 2.0–3.0)
overlapping with initial tinzaparin 175
IU/kg once daily (5–10 days) (N=450) 
Table 2 Diagnostic criteria for VTE
VTE before randomisation Recurrent VTE after randomisation
Symptomatic
VTE
• All patients must have diagnostic imaging performed
of both legs and the lungs in order to determine
baseline presence or absence of DVT or PE.
• Standard objective imaging is required to diagnose recurrent
VTE. If there are symptoms from the leg(s) AND lungs, objective
imaging is required for both sites.
• Diagnostic imaging results for DVT: • Diagnostic imaging results for recurrent DVT:
- A non-compressible venous segment of the proximal
deep veins in the legs, including iliac, femoral and
popliteal veins.
- A non-compressible venous segment of the deep veins (proximal
and/or distal) in the legs that had normal compression at baseline.
- An intraluminal filling defect on venography,
CT scan or MR venography of the proximal deep
veins in the leg.
- A new or extension of 5 cm or greater of intraluminal filling
defect on venography, CT scan or MR venography of the deep
veins in the leg, including inferior vena cava.
• Diagnostic imaging results for PE:
- An extension of non-visualisation of the deep veins of the leg in
the presence of a sudden cut-off on venography, CT scan or MR
venography.- An intraluminal filling defect on CT pulmonary
angiography. • Diagnostic imaging results for recurrent PE:
- A perfusion defect of at least 75% of a segment
with a local normal ventilation result (mismatch defect)
on ventilation-perfusion lung scintigraphy
(high-probability scan).
- A new or extension of an existing intraluminal filling defect
on CT pulmonary angiography.
- A non-high, non-diagnostic ventilation-perfusion lung
scan with confirmed DVT.
- A new sudden cut-off of vessels more than 2.5 mm in diameter
on CT pulmonary angiography.
- A new perfusion defect of at least 75% of a segment with a local
normal ventilation result (mismatch defect) on ventilation-perfusion
lung scintigraphy (high-probability scan).
- A non-high, non-diagnostic ventilation-perfusion lung scan with
confirmed DVT.
• Diagnostic criteria for fatal PE:
- Objective testing as above associated with death.
- Autopsy finding of PE contributing to death.
- Sudden and unexplained death within the 6-month study period
which cannot be attributed to a documented cause and for which
PE is the most probable cause.
Incidental VTE • Not valid as an inclusion criterion. • Incidental PE or DVT are defined as thrombi that were reported
during imaging testing performed for reasons other than for
suspected PE or DVT.
• Diagnosis of incidental VTE during the required
baseline imaging represents the baseline status.
• The same diagnostic imaging criteria for recurrent DVT or PE
apply to confirming the presence of an incidental DVT or PE.
• Incidental DVT is only included as an outcome if located in the
popliteal or more proximal leg veins.
• Incidental PE is only included as an outcome if located in
segmental or more proximal pulmonary arteries.
• In patients with incidental PE involving subsegmental pulmonary
arteries only, a compression ultrasound showing a new DVT is
necessary to confirm a recurrent thrombotic event.
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<6 months; basal cell carcinoma or non-melanoma skin can-
cer (in the absence of any other cancer diagnosis); creatinine
clearance ≤20 mL/min (according to the abbreviated Modi-
fication of Diet in Renal Diseases formula); contraindications
to anticoagulation; known hypersensitivity to study me-
dications; history of heparin-induced thrombocytopenia
(HIT); therapeutic anticoagulation for >72 hours pre-
randomisation; receiving therapeutic anticoagulation at the
time of VTE; unlikely to comply with protocol; participationin another interventional study; women of childbearing po-
tential or fertile men not using effective contraception.
The eligibility criteria are very similar to those of pre-
vious trials to facilitate cross-trial comparison and pos-
sible meta-analysis of the results.
Consent
Written, informed consent was obtained from all patients
for participation in the study after a review of the protocol,
their responsibilities and their rights. Consent was also
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storage of blood samples, as outlined in the protocol, to
allow regulatory monitoring, statistical analysis and peer-
review presentation and publication of the study results.
Randomisation and concealment
Randomisation must occur within 72 hours after the
qualifying thrombotic event is objectively confirmed, or
within 72 hours of starting therapeutic anticoagulant
treatment for a suspected thrombotic event that is then
objectively confirmed, whichever time point comes first.
Prior to randomisation, all patients must have diagnostic
imaging performed for both DVT and PE in order to
document asymptomatic DVT or PE at baseline. At ran-
domisation, participants are assigned to either tinzaparin
at full treatment doses (175 IU/kg once daily) for
6 months (180 days; for this study, 1 month will equal a
period of 30 days) in the experimental arm, or initial
tinzaparin treatment for 5–10 days overlapping with
dose-adjusted warfarin (target international normalisa-
tion ratio [INR] 2.0–3.0) for 6 months in the control
arm. Treatment assignment is pre-planned according to
a computer-generated randomisation schedule in a 1:1
ratio and concealed until individual randomisation using
an interactive voice response system (IVRS) by tele-
phone. In order to balance treatment groups, a stratified
randomisation scheme has been applied that takes into
account the following: tumour (known distant metasta-
sis, no distant metastasis, haematological malignancy);Table 3 Dosage guide for tinzaparin
175 IU/kg body weight sub
Syringe size Body weight (kg) ro
up or down to near













2 × 10,000 IU in 0.5 mL 104–124
1 × 10,000 IU in 0.5 mL and 1 × 14,000 IU in 0.7 mL 125–145
2 × 14,000 IU in 0.7 mL 146–165
1 × 14,000 IU in 0.7 mL and 1 × 18,000 IU in 0.9 mL 166–183geographical region (four different regions); and known
history of previously diagnosed VTE (yes or no).
Study treatments
All patients are instructed on the subcutaneous adminis-
tration of pre-filled syringes of tinzaparin. Patients are
given labelled kits containing syringes of tinzaparin
containing 0.5 mL (10,000 IU), 0.7 mL (14,000 IU) or
0.9 mL (18,000 IU) of tinzaparin, whichever is most ap-
propriate for their weight. The exact dose of tinzaparin
administered once daily is based on the dosage table
according to patient body weight at 175 IU/kg, rounded
to the nearest 1,000 IU (Table 3). Those assigned to re-
ceive tinzaparin for 6 months receive a 30-day supply at
the initial visit and then at scheduled monthly visits
thereafter. Those assigned to tinzaparin and warfarin re-
ceive a 10-day supply of tinzaparin and a 30-day supply
of warfarin containing 1-mg, 3-mg and 5-mg tablets.
More warfarin is dispensed at follow-up visits. Warfarin
is taken once daily at a dose adjusted to maintain a
therapeutic INR between 2.0 and 3.0. The use of a war-
farin dosing nomogram is encouraged. The first injection
of tinzaparin in both groups is administered as soon as
possible after randomisation. All patients complete a
diary to record the date and time of injections and doses
of warfarin, if appropriate. Temporary discontinuation of
study drugs not exceeding 3 weeks is permitted for
thrombocytopenia (platelet count less than 50 × 109/L),
a bleeding event, or if the patient must undergo anycutaneously once daily
unded
est kg
Units Volume to expel from syringe
















20,000 None 2 × 0.5
24,000 None 1 × 0.5 and 1 × 0.7
28,000 None 2 × 0.7
32,000 None 1 × 0.7 and 1 × 0.9
Lee et al. BMC Cancer 2013, 13:284 Page 7 of 13
http://www.biomedcentral.com/1471-2407/13/284invasive procedures. If study drug is held or missed for
more than three consecutive weeks, then the patient will
be considered to have permanently discontinued study
drug.
Primary and secondary efficacy outcomes
The primary composite endpoint is time in days to the
first occurrence up to Day 180 of any of the following
five objectively documented components: symptomatic
DVT; symptomatic non-fatal PE; fatal PE; incidental
proximal DVT (popliteal vein or higher); incidental
proximal PE (segmental arteries or larger). Each of these
components will be considered separately as secondary
efficacy endpoints. In addition, a secondary composite
efficacy endpoint of symptomatic DVT, symptomatic
non-fatal PE and fatal PE will be analysed.
Incidental PE or DVT are defined as thrombi that are
reported during imaging testing performed for other rea-
sons (e.g. cancer staging) and not for suspected VTE. Pa-
tients may or may not have symptoms of PE or DVT at
the time of the test. Incidental PE is only included as an
outcome if located in segmental or more central pul-
monary arteries; incidental DVT is only included as an
outcome if it involves the popliteal or more proximal
veins in the legs/pelvis. More distal thrombotic events,
such as isolated subsegmental PE and calf DVT, found
incidentally are not included in the primary composite
efficacy outcome because of conflicting data on their
diagnostic accuracy, clinical significance and require-
ment for anticoagulant treatment [15,35,36].
All of these endpoint thrombotic events must be ob-
jectively confirmed using standardised imaging tech-
niques and meet pre-specified diagnostic criteria for
recurrent DVT and/or PE (Table 2). Only those events
confirmed and validated by the Independent Central Ad-
judication Committee will be included in the primary ef-
ficacy analysis.
Secondary outcomes
Secondary endpoints include: bleeding (major bleeding,
clinically relevant non-major bleeding); all-cause mortal-
ity; HIT; risk factors for recurrent VTE; PTS; health-
related QoL; and healthcare resource utilisation.
Major bleeding will be defined according to Inter-
national Society on Thrombosis and Haemostasis (ISTH)
criteria [37]: bleeding with a fall in haemoglobin of ≥2 g/
dL; bleeding requiring a transfusion of ≥2 units of red
cells or whole blood; bleeding that occurs in a critical lo-
cation, i.e. intracranial, intraspinal, intraocular, retroperi-
toneal, intraarticular or pericardial; or bleeding that
causes death. All non-major bleedings that require any
medical or surgical intervention will be classified as ‘clin-
ically relevant non-major bleeding’. Bleeding episodes
not meeting either of the above criteria will be classifiedas trivial bleeding. Only those bleeding events that occur
within 24 hours after the last dose of study drug and
confirmed by central adjudication will be included in the
analysis as a secondary outcome. Bleeding events occur-
ring after that period and up to 1 month after the last
dose will be considered as adverse events.
All deaths will be adjudicated and cause of death will
be classified as due to: PE (confirmed by autopsy or ob-
jective imaging or sudden explained death for which PE
is the most probable cause); cancer progression; bleed-
ing; or other causes.
The diagnosis of HIT requires both clinical and la-
boratory/diagnostic confirmation that is consistent with
standard practice, including the use of the Warkentin
4 T score [38]. Laboratory analyses to investigate for
HIT are performed locally but will be confirmed at the
central laboratory. All cases of reported HIT will be sent
for central adjudication.
Risk factors for recurrent VTE
VTE risk factors (e.g. tumour type, body mass index
[BMI], platelets, haemoglobin and leucocytes) will be
assessed at baseline and at the time of a VTE event. Co-
agulation biomarkers (D-dimer, tissue factor, C-reactive
protein, Factor VIII and soluble P-selectin) will be
assessed at baseline and end-of-treatment visits.
Post-thrombotic syndrome
The presence and severity of PTS will be assessed using
the Villalta scale [39] at baseline, each monthly visit and
the end of the 1-month post-treatment follow-up period.
The Villalta scale classifies PTS as mild if the score is 5–
9, moderate if the score is 10–14, and severe if the score
is ≥15 or a venous ulcer is present.
Patient-reported QoL
Patient-reported QoL will be assessed using the EQ-5D
questionnaire (available at www.euroqol.org) at baseline,
each monthly visit, Day 180 and at the post-treatment
follow-up visit. The six-item measure generates a de-
scriptive profile and five of these items can be converted
into single index value for health status. The five-item
descriptive portion addresses five health dimensions
(mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression), with respondents indicating one of
three possible responses for each dimension. The sixth
item is a visual analogue scale (0–100) that is used to re-
port overall health status.
Healthcare resource utilisation
Healthcare resource utilisation data will be collected for
assessments at each monthly visit and the post-
treatment follow-up visit. Only healthcare resources
leading to major cost drivers will be collected. These will
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drug, etc.), routine laboratory tests, patient INRs, un-
scheduled clinical visits, diagnostic tests relevant for
VTE diagnosis, blood transfusions, the occurrence of
major-bleeding-related events that were possibly or
probably due to the study drugs, and costs for the man-
agement of patients who develop recurrent VTEs (e.g.
hospitalisation).
Study follow-up
The day of randomisation is considered as Day 1, Visit 1.
Subsequent visits occur on Day 7, Day 14, Day 30
(Month 1) and then every 30 days (Months 2–6) until
Day 180. Patients stopping study treatment prior to Day
180 for any reason except death are followed up by tele-
phone contacts in place of scheduled monthly visits until
Day 180.
Each scheduled visit and telephone contact include a
standardised assessment of the signs and symptoms of
recurrent VTE. All patients are advised to contact the
investigator or delegated site staff if the patient experi-
ences signs and symptoms of VTE between scheduled
visits or telephone calls. If signs and symptoms assessed
by the investigator or delegated staff are consistent with
a recurrent VTE, the patient is advised to return to the
clinic urgently for an unscheduled visit for objective test-
ing in order to confirm or refute the suspected recurrent
VTE. If the recurrent VTE is confirmed, end-of-treat-
ment assessments are performed and the patient is
treated according to local practice and investigator’s dis-
cretion. If the recurrent VTE is not confirmed, the pa-
tient continues study medication and returns for the
next scheduled visit as planned. Diagnosis of symptom-
atic DVT/PE (both at randomisation and recurrence)
must be made by appropriate objective imaging using
standard diagnostic criteria (Table 2). Any protocol-
defined incidental VTE identified after stopping of study
drug will be included in the primary outcome analysis.
All patients are followed for the primary composite ef-
ficacy endpoint and for all-cause death up to Day 180
from day of randomisation or death (whichever occurs
first), regardless of study drug status. Patients are
followed for bleeding events until the last dose of study
drug, and for 1 month (30 days) following the last dose
of study treatment for all other secondary endpoints.
Health-related QoL is followed up to at least Day 180,
and for an additional 1 month if Day 180 is the last dose
of study treatment. Adverse events and serious adverse
events (AE/SAEs) are recorded while a patient is receiv-
ing study drug. SAEs are recorded up to 1 month after
the last dose of study drug. Coding of AE/SAEs use
the Medical Dictionary for Regulatory Activities and se-
verity is graded according to the National Cancer
Institute Common Terminology Criteria for AEs v4.03.If a patient dies during the 6-month treatment period,
all reasonable efforts will be made to ascertain the fol-
lowing information: the cause of death and obtain a copy
of the autopsy report (if available); whether the patient
experienced any outcome or SAEs between the last visit
or telephone contact and the time of death; and when
the last dose of study treatment was taken.
Study monitoring and oversight
CATCH has approval from the institutional review
boards or independent ethics committees of all investi-
gational sites. The trial has been registered with
ClinicalTrials.gov (NCT01130025) and was designed in
accordance with Good Clinical Practice guidelines.
The Independent Adjudication Committee (IAC) is
blinded to study medication assignment and comprises
thrombosis, oncology and bleeding experts independent
of the study and the study sponsors. The blinded IAC is
responsible for adjudicating the following: all efficacy
endpoints (i.e. DVTs, PEs and causes of death) occurring
up to Day 180; bleeding events occurring up to 24 hours
after last dose of study treatment; and HIT events occur-
ring up to 1 month after last dose of study treatment.
The adjudication results will be the basis for final ana-
lysis of recurrent VTE, bleeding, HIT and deaths.
The independent Data Monitoring Committee com-
prises clinicians and methodologists independent of the
study and the study sponsors and is responsible for moni-
toring the progress of the study and safety of the patients.
The Data Monitoring Committee recommended that the
trial continue as planned during its last regular review in
August 2012.
Study management
In close collaboration with the contract research organ-
isation to which the study was outsourced, study-specific
training is conducted to ensure protocol adherence and
data quality. Initial training of Principal Investigators
and site staff (sub-investigators, study coordinators and
nurses, pharmacists, and radiologists) was conducted at
regional investigator meetings. During the recruitment
phase of the study, additional investigator meetings are
held regionally, as well as on country and site levels.
During the continuous clinical and medical monitoring
of the study, a series of help tools have been developed
for training and communication purposes. The tools in-
clude procedure manuals, guidance documents, fliers,
posters and a web-based study portal. A study newsletter
is distributed on a monthly basis and sites are supported
by visits of senior medical affairs representatives from
the sponsor. All sites are monitored clinically to ensure
data quality and study protocol adherence. Sites are
audited to provide quality control reports, and sites also
receive sponsor oversight monitor visits. Data quality
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listing-based approach. Patient profiles are also adopted to
ensure patient level oversight, including INR monitoring.
Overall study and patient safety is assured by the Data
Monitoring Committee. The Steering Committee also
convenes regularly to monitor study progress.
Statistical methods
Sample size estimation
This trial aims to demonstrate that long-term treatment
with tinzaparin will show greater benefits in reducing
the risk of recurrent VTE versus warfarin. Reported inci-
dence rates of the primary endpoint vary in the popula-
tion of cancer patients. For patients receiving VKA
treatment, the CLOT trial supports an incidence rate of
15.8% [28], while meta-analyses support an incidence
rate of 12.6% [40] or 14.3% [41]. Our sample size is
based on a relative risk reduction of 50%, with an esti-
mated event rate of 12.6% in the control group. Using a
time-to-event approach with a two-sided significance
level of α = 0.05 and an overall power of 90%, a sample
size of 847 patients will be required to detect the above
difference. Incorporating an expected dropout rate of
5%, it is planned that 900 patients will be randomised:
450 patients in the tinzaparin arm and 450 patients in
the control arm. A sample size re-estimation will be
conducted on blinded data when approximately 25% of
patients have completed the treatment period, died or
been lost to follow-up, to assess the appropriateness of
the assumptions. The assumed relative risk reduction of
50% will remain unchanged.
Statistical analyses
Descriptive statistics of the patient characteristics will be
presented for all randomised patients and for patients
grouped according to treatment group and by stratum.
All efficacy criteria will be analysed for the full analysis
set (FAS; intention to treat). In addition, the primary ef-
ficacy criterion will be analysed for the per-protocol (PP)
analysis set and used as supportive data. The efficacy
analysis period is defined as the period from randomisa-
tion up to 180 days after randomisation and at least
24 hours following the last administration of investiga-
tional product. All recurrent VTE outcomes confirmed
by central adjudication occurring during this period will
be eligible for the primary efficacy analysis. Comparison
will be based on the time to first recurrent event per pa-
tient. To account for competing risks, Gray’s test will be
used for comparing cumulative incidence functions. The
cumulative incidence function will be estimated separ-
ately for the two treatment groups using a bivariate ap-
proach and the corresponding 95% confidence interval
(CI) will be computed. The competing risks considered
in this study are deaths other than fatal PEs. An interimanalysis of the primary endpoint will be performed by
the Data Monitoring Committee when 50% of patients
have completed treatment, died or been lost to follow-
up. The decision will be primarily based on the primary
efficacy criterion. The study can be stopped early in the
event of superiority or futility.
All secondary efficacy endpoints will be analysed as
described for the primary efficacy endpoint. For each
time-to-event analysis, the components not defined as
the event of interest will be considered a competing risk;
95% CIs will be calculated and P values will be corrected
for multiplicity using the Hochberg method. For both
primary and secondary efficacy analyses, the assessment
of recurrent VTE from the blinded IAC will be used;
analysis of the investigator assessment of recurrent VTE
will not be performed.
Overall mortality will be summarised with Kaplan–
Meier estimates and compared between treatment
groups using a two-sided log-rank test. An estimate of
the treatment effect (hazard ratio and associated CI) will
be obtained via Cox regression including all stratification
factors. The proportion of patients with a major bleeding
event or with clinically relevant non-major bleeding will
be compared between groups using Fisher’s exact test.
Similar to the primary endpoint, in order to correct for
competing risks, a cumulative incidence approach will
be used to analyse bleeding data. Competing risks will
be deaths from all causes other than fatal bleeding.
An exploratory analysis will be performed to assess the
association of clinical baseline characteristics with recur-
rent symptomatic and/or incidental VTE and bleeding
in patients receiving anticoagulant therapy. The presence
and severity of PTS will be analysed using the Villalta
scale; comparison within and between treatment groups
will be performed in addition to analysis of the change
in severity over time. For assessment of health-related
QoL, descriptive statistics will be produced for the five
EQ-5D dimensions (i.e. mobility, self-care, usual activ-
ities, pain/discomfort, and anxiety/depression), visual
analogue scale, and utility index at each assessment for
patients in the tinzaparin and control groups. Dimen-
sional outcomes and utility indices of the EQ-5D will
then be assessed using multivariate mixed models for a
repeated-measures analysis. As a secondary endpoint in
the QoL analysis, ‘clinical stability’ will be evaluated, de-
fined as an improvement or <10% drop in the utility
index of the EQ-5D when measured during two con-
secutive monthly assessments. Clinical stability and de-
terioration between treatment groups will be analysed
using logistic regression analysis, Kaplan–Meier curves
and Cox proportional hazards regression. Healthcare re-
source utilisation associated with the prevention of sec-
ondary VTEs will be assessed between groups for a
reference country using non-parametric statistical
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addition, the incremental cost per VTE avoided and
quality-adjusted life year (QALY) gained with tinzaparin
will also be determined.
Results and discussion
The main aim of the CATCH trial is to confirm the su-
perior efficacy of tinzaparin over warfarin for the sec-
ondary prevention of VTE in patients with active cancer.
CATCH will extend and broaden the findings from pre-
vious clinical trials comparing LMWH with a VKA such
as warfarin by addressing several current knowledge
gaps in the management of VTE in patients with cancer.
These include the generation of prospective data on the
clinical significance of incidental VTE and the potential
identification of risk factors predicting recurrence, both
of which will add information that may help to further
tailor therapy. CATCH will also include specific assess-
ment of the incidence and severity of PTS in patients
with cancer. This has not previously been performed
despite PTS being a common and burdensome compli-
cation of DVT [42]; the results will add to existing data
that have shown that long-term treatment with
tinzaparin significantly reduces the incidence of PTS and
leg ulcers in a broader patient population with acute
DVT [43]. Little information exists concerning the needs
and preferences of cancer patients at risk of recurrent
VTE [24]; the patient-reported outcomes from CATCH
will provide important insights into QoL aspects of pa-
tient care. Finally, unlike the CLOT trial, which used a
reduced dose of dalteparin after 1 month, CATCH will
use tinzaparin at the full therapeutic dose for 6 months.
The rationale for choosing this dose and several key de-
sign features of the CATCH trial are discussed below.
Rationale for tinzaparin and therapeutic dose in the trial
There are pharmacological and clinical data to support
the use of tinzaparin at a therapeutic dose for the treat-
ment of cancer-associated thrombosis. Tinzaparin has
the highest mean molecular weight (approximately
6,500 Da) of the commercially available LMWHs and is
least dependent on renal clearance [44]. This is sup-
ported by findings from clinical studies, which have
shown that treatment doses of tinzaparin do not accu-
mulate in patients with mild to severe renal insufficiency
(clearance ≥20 mL/min) [45,46]. Tinzaparin can be
used in elderly patient populations without any dose re-
ductions at both prophylactic (4500 anti-Xa IU) and
therapeutic doses (175 anti-Xa IU/kg) [45-47]. The elim-
ination profile of tinzaparin is an important consider-
ation among patients with cancer, of whom many are
elderly or have renal impairment. Tinzaparin is also the
most reversible of any LMWH, with 65–85% of its anti-
Xa activity neutralised by protamine sulphate [48-50].Prolonged treatment with tinzaparin at a therapeutic
dose (175 anti-Xa IU/kg) to prevent VTE recurrence has
been shown to be effective and safe in several clinical
studies [27,43,51-53]. In particular, the effect of
tinzaparin (175 anti-Xa IU/kg) was evaluated over a 90-
day period in the Main-LITE study of acute symptomatic
DVT, in which approximately one quarter of subjects
had cancer [27,52]. In the 200 patients with cancer, the
primary outcome of VTE recurrence at the end of the 3-
month treatment period was 6% in those receiving
tinzaparin and 10% in those receiving VKA (difference
-4.0; 95% CI -12.0 to 4.1); at 12 months, the respective
rates were 7% versus 16% (P = 0.04). Treatment with
tinzaparin was not associated with an increased risk of
bleeding compared with the VKA arm. In addition, a re-
lated study (Home-LITE) compared long-term treatment
at home with tinzaparin or usual care in a broad popula-
tion of patients with DVT and showed that tinzaparin
use was associated with a lower risk of PTS [43]. The
single, therapeutic-dose regimen of tinzaparin in
CATCH will simplify treatment and perhaps produce
lower risks of recurrent VTE.
Rationale for warfarin as comparator in the control group
Initial consideration was given to using dalteparin as the
control group comparator because it is the only LMWH
approved for extended use in the prevention of recurrent
VTE in patients with cancer, but it is still not considered
the standard of care in many countries and warfarin re-
mains a commonly used anticoagulant in cancer patients
worldwide [54-58]. This may be a reflection of the un-
desirable mode of drug delivery of LMWHs (requiring
once- or twice-daily subcutaneous injections), as well as
their substantially higher drug cost compared with VKAs.
Furthermore, comparing tinzaparin with dalteparin
with efficacy as the primary outcome would require a
non-inferiority study design, as there is no evidence that
one LMWH is superior in efficacy over another. In fact,
a randomised controlled trial that compared tinzaparin
with dalteparin for the initial treatment of VTE in a
mixed population of non-cancer and cancer patients
found no difference between the two LMWHs [59].
Based on a planned interim analysis, the investigators
determined that a study including 16,433 per group
would be needed to demonstrate a statistically signifi-
cant difference between the two LMWHs. Therefore, the
study was terminated early based on this futility ration-
ale. To perform a non-inferiority study to compare
tinzaparin with dalteparin would also seem futile in ad-
vancing patient care, as the two drugs are already com-
monly used interchangeably and both are recommended
for extended treatment of cancer-associated thrombosis.
Consequently, we believe that it is more beneficial to
patient care and scientific advancement if a robust, well-
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tinzaparin with warfarin and to confirm the results
reported in the previous trials. Such a Phase III trial also
provides the opportunity to prospectively investigate im-
portant clinical outcomes that have not been addressed
and which are relevant for patients and support
individualised care, including PTS, patient-reported
QoL, predictors and markers of recurrent VTE and
bleeding, and healthcare resource utilisation.
Rationale for open-label design
An open-label design could be a source of potential bias.
However, a double-blind study in oncology patients
would be ethically and practically challenging as it would
expose them to excessive burden: subcutaneous injec-
tions of a placebo drug in patients assigned to warfarin
treatment and placebo tablets with sham INR monitor-
ing requiring multiple unnecessary blood draws in patients
assigned to long-term tinzaparin treatment. It is also very
difficult to generate convincing or realistic sham INRs in
those patients receiving long-term tinzaparin to reflect
changes that often result from chemotherapy. Further-
more, it is potentially dangerous to mask the anticoagulant
used in those with severe thrombocytopenia. For example,
a false positive result on a HIT assay in a patient who is re-
ceiving warfarin therapy could be switched to argatroban
for HIT treatment. Lastly, masking study drug frequently
heightens patient anxiety and this is a particularly sensitive
issue in oncology patients in whom the risks of bleeding
and recurrent VTE are so much higher than in the general
population. Hence, an open-label design was chosen for
patient safety and preference and to minimise the negative
impact on their QoL. To minimise the potential bias of
this design, all reported VTE and bleeding events, HIT
and cause of death are centrally adjudicated by an inde-
pendent expert committee that is blinded to treatment
assignment.
Rationale for including incidental VTE as an efficacy endpoint
Incidental VTE is now commonly reported in cancer pa-
tients because of the prevalence of routine CT imaging for
follow-up. Although the exact history and optimal treat-
ment of incidental thrombotic events remain uncertain,
we included these events in the primary composite end-
point for several reasons: 1) the majority of these events
are associated with symptoms consistent with PE or DVT
[14]; 2) several studies have shown that incidental VTEs
are clinically significant events with similar prognosis to
symptomatic VTE [60,61]; 3) expert consensus guidelines
recommend treatment with therapeutic anticoagulation
when incidental proximal DVT or PE are reported [15]. In
addition, emerging evidence in cancer patients shows that
asymptomatic VTE rates correlate directly with symptom-
atic VTE rates and survival [16,17].Conclusions
The results obtained from the CATCH trial will add sig-
nificantly to the knowledge of the efficacy, safety and cost
effectiveness of the LMWH tinzaparin in the prevention
of recurrent VTE in cancer patients. The findings should
provide greater therapeutic choice and better understand-
ing of the long-term outcomes of patients with cancer and
thrombosis.
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